News

Medigene AG: Medigene to participate in three upcoming international conferences

Martinsried/Munich, 02 March, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming scientific and business development conferences: 
             

  • BIO-Europe Spring 2015 - 9th Annual International Partnering Conference

            Date: 09 - 11 March 2015
            Location: Paris, France
             

  • 9. Forum Life Science

            Date: 11 - 12 March 2015
            Location: Munich, Germany       
            Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will conduct a presentation on 12 March titled "The power of T cells in terms of cancer therapy"
             

  • 26th Annual Cancer Progress Conference

            Date: 17 - 18 March 2015
            Location: New York, USA
            Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will be panelist at a discussion on 17 March focussing the topic "Immunotherapy II: Engineered Cell Therapy"
             

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe